Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 27;8(2):19.
doi: 10.3390/cancers8020019.

Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go

Affiliations
Review

Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go

Rachel J Buchsbaum et al. Cancers (Basel). .

Abstract

Cancers are heterogeneous tissues comprised of multiple components, including tumor cells and microenvironment cells. The tumor microenvironment has a critical role in tumor progression. The tumor microenvironment is comprised of various cell types, including fibroblasts, macrophages and immune cells, as well as extracellular matrix and various cytokines and growth factors. Fibroblasts are the predominant cell type in the tumor microenvironment. However, neither the derivation of tissue-specific cancer-associated fibroblasts nor markers of tissue-specific cancer-associated fibroblasts are well defined. Despite these uncertainties it is increasingly apparent that cancer-associated fibroblasts have a crucial role in tumor progression. In breast cancer, there is evolving evidence showing that breast cancer-associated fibroblasts are actively involved in breast cancer initiation, proliferation, invasion and metastasis. Breast cancer-associated fibroblasts also play a critical role in metabolic reprogramming of the tumor microenvironment and therapy resistance. This review summarizes the current understanding of breast cancer-associated fibroblasts.

Keywords: breast cancer; cancer-associated fibroblasts; tumor microenvironment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J. Clin. Oncol. 2005;23:7350–7360. doi: 10.1200/JCO.2005.03.3845. - DOI - PubMed
    1. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., et al. Ki67 index, HER2 status, and prognosis of patients with luminal b breast cancer. J. Natl. Cancer Inst. 2009;101:736–750. doi: 10.1093/jnci/djp082. - DOI - PMC - PubMed
    1. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009;27:1160–1167. doi: 10.1200/JCO.2008.18.1370. - DOI - PMC - PubMed
    1. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: A critical review. J. Clin. Oncol. 2008;26:2568–2581. doi: 10.1200/JCO.2007.13.1748. - DOI - PubMed
    1. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010;28:1684–1691. doi: 10.1200/JCO.2009.24.9284. - DOI - PubMed

LinkOut - more resources